Immune-stimulating antibodies that target the receptor CD40 are emerging as promising therapies for pancreatic cancer, but they’ve only shrunk tumors in about half of patients who received them, along with chemotherapy, in clinical trials.
Researchers from the University of Pennsylvania’s Abramson Cancer Center believe they’ve found one key to that lack of response. And it may be targetable with different drug combinations, they said. Read more . . .